Morphothiadine Mesylate/Ritonavir

甲磺酸莫非赛定/利托那韦

Report date: 2025/06/18 10:40:47
NME

Base Information

Drug NameMorphothiadine Mesylate/Ritonavir
Drug Alias Name莫非赛定利托那韦片
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCapsid protein inhibitorsHuman immunodeficiency virus type 1 protease inhibitorsCytochrome P450 3A4 inhibitors
TargetsCapsid proteinHuman immunodeficiency virus type 1 proteaseCytochrome P450 3A4
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Morphothiadine MesylateRitonavir
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A